| 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 新大洲A | 000571 | 股权激励限售流通 | 980.75万 | | 中钨高新 | 000657 | 股权激励限售流通 | 72.06万 | | 东方钽业 | 000962 | 股权激励限售流通 | 156.87万 | | 内蒙一机 | 600967 | 股权激励限售流通 | 663.31万 | | 三花智控 | 002050 | 股权激励限售流通 | 701.47万 | | 大禹节水 | 300021 | 股权激励限售流通 | 76.17万 | | 瑞普生物 | 300119 | 股权激励限售流通 | 69.76万 | | 海南矿业 | 601969 | 股权激励限售流通 | 364.05万 | | 吉翔股份 | 603399 | 股权激励限售流通 | 309万 | | 华电重工 | 601226 | 股权激励限售流通 | 388.82万 | | 星徽股份 | 300464 | 股权激励限售流通 | 576万 | | 博济医药 | 300404 | 股权激励限售流通 | 20万 | ...

Group 1 - The hepatitis concept sector declined by 1.36%, ranking among the top declines in concept sectors, with major declines seen in companies like Hai Chen Pharmaceutical, Hainan Hai Pharmaceutical, and Nuotai Biological [1][2] - Among the 18 stocks that rose, Fu Rui Co., Ltd., Fozi Pharmaceutical, and *ST Shuangcheng led with increases of 6.42%, 5.79%, and 5.03% respectively [1][2] - The hepatitis concept sector experienced a net outflow of 859 million yuan from main funds, with 88 stocks seeing net outflows, and five stocks exceeding 50 million yuan in outflows [2][6] Group 2 - Hai Chen Pharmaceutical had the highest net outflow of main funds at 119 million yuan, followed by Zhongsheng Pharmaceutical, Nuotai Biological, and Lu Kang Pharmaceutical with outflows of 95.25 million yuan, 92.01 million yuan, and 88.21 million yuan respectively [2][6] - The stocks with the highest net inflows included Fu Rui Co., Ltd., Zhongheng Group, and Te Bao Biological, with inflows of 52.72 million yuan, 39.98 million yuan, and 37.06 million yuan respectively [2][6]

Core Viewpoint - Boji Pharmaceutical's stock closed at 8.38 yuan, with a PE ratio of 198.65, significantly higher than the industry average of 38.49 [1][2] Company Overview - Boji Pharmaceutical provides comprehensive CRO services for pharmaceutical companies and research institutions, focusing on new drug and medical device development [1] - The company has participated in various academic events, enhancing its brand image and industry connections [1] Financial Performance - For Q1 2025, Boji Pharmaceutical reported revenue of 139 million yuan, a year-on-year decrease of 17.06%, and a net profit of 3.90 million yuan, down 76.38% [2] - The company's gross profit margin stands at 30.60% [2] Market Position - Boji Pharmaceutical ranks 43rd in the medical services industry based on PE ratio, with a total market capitalization of 3.211 billion yuan [1][2] - The company has received several accolades, including being ranked 8th among the top 20 CRO companies in China for 2024 [1]

博济医药 2024 年年度股东大会法律意见书 致：博济医药科技股份有限公司 博济医药科技股份有限公司（下称"博济医药"或"公司"）2024 年年度 股东大会（以下简称"本次股东大会"）于 2025 年 5 月 16 日下午 14 时 30 分在 广州市天河区华观路 1933 号万科云广场 A 栋 7 层公司会议室一召开。北京市康 达（广州）律师事务所（以下简称"本所"）受博济医药委托，根据《中华人民 共和国公司法》（下称"《公司法》"）、《中华人民共和国证券法》(下称"《证 券法》")、《上市公司章程指引》（下称"《章程指引》"）、《上市公司股 东大会规则》（下称"《股东大会规则》"）、《深圳证券交易所上市公司股东 大会网络投票实施细则》（下称"《深交所网络投票实施细则》"）等法律、法 规、规范性文件以及《博济医药科技股份有限公司章程》（下称"博济医药《公 司章程》"）的规定，对本次股东大会的召集、召开程序、出席会议人员资格以 及表决方式、表决程序、表决结果等事项进行见证并出具本法律意见书。 为出具本法律意见书，本所律师对博济医药本次股东大会所涉事宜进行了审 查，查阅了相关会议文件，并对有关事项进行了必要的核 ...

2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300404 证券简称：博济医药 公告编号：2025-043 博济医药科技股份有限公司 特别提示 1、本次股东大会无否决议案的情况； 2、本次股东大会未涉及变更前次股东大会决议的情形； 3、本次股东大会以现场投票和网络投票相结合的表决方式。 一、会议召开情况 1、会议召开时间 （1）现场会议召开时间：2025 年 5 月 16 日（星期五）下午 14:30。 （2）网络投票时间：2025 年 5 月 16 日。其中，通过深圳证券交易所交易 系统进行网络投票的具体时间为：2025 年 5 月 16 日上午 9:15-9:25，9:30-11:30， 下午 13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 5 月 16 日 9:15-15:00。 2、会议地点：广州市天河区华观路 1933 号万科云广场 A 栋 7 层公司会议 室一。 3、召开方式：现场投票和网络投票相结合的方式。 4、召集人：博济医药科技股份有限公司第五届董事会 5、 ...

2024 年年度持续督导跟踪报告 | 保荐人名称：广发证券股份有限公司 | 被保荐公司简称：博济医药 | | --- | --- | | 保荐代表人姓名：黄晟 | 联系电话：020-66338888 | | 保荐代表人姓名：杨鑫 | 联系电话：020-66338888 | 一、保荐工作概述 广发证券股份有限公司 关于博济医药科技股份有限公司 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2.督导公司建立健全并有效执行规章制度的情 | | | 况 | | | （1）是否督导公司建立健全规章制度（包括但 不限于防止关联方占用公司资源的制度、募集 | | | | 是 | | 资金管理制度、内控制度、内部审计制度、关 | | | 联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 自承接持续督导工作后，保荐机构每月 | | | 查询公司募集资金专户资金变动情况 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-042 博济医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第五届董事会第十三次会议和第五届监事会第十二次会议，审议通过了《关于注 销部分股票期权的议案》。根据公司《2022 年股票期权激励计划（草案）》等 有关规定，公司 1 名激励对象因个人原因离职导致其不再具备激励资格，公司注 销其已授予但尚未行权的股票期权 13,440 份。具体内容详见公司于 2025 年 4 月 26 日在巨潮资讯网上披露的《关于注销部分股票期权的公告》（公告编号： 2025-030）。 经中国证券登记结算有限责任公司深圳分公司审核确认，公司上述股票期权 注销事宜已办理完成。本次注销的部分股票期权尚未行权，注销后不会对公司股 本造成影响。 特此公告。 博济医药科技股份有限公司董事会 博济医药科技股份有限公司 关于部分股票期权注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次注销 2022 年股票期权激励计划中已授予但尚未行权的部分股票期 权数量为 13,4 ...

Group 1: ZTE Information - ZTE Information has approximately 7,000 active users for SnapDevelop and plans to release a paid commercial version in the future [1] - EazyDevelop, which focuses on rapid development using AI technology, will support MCP calls and is set to launch a free trial version [1] - Baidao Software has made breakthroughs in RISC-V firmware and is collaborating with major companies like Huawei and Lenovo [1] Group 2: Boji Pharmaceutical - Boji Pharmaceutical's new orders for 2024 are projected to be 1.515 billion yuan, a year-on-year increase of 30.07% [2] - The company aims for a revenue target of 682 million yuan for 2025, with a focus on clinical business and technology transfer services [2] - The company is exploring AI applications in clinical trial processes and has seen a 20% growth in traditional Chinese medicine CRO orders [2] Group 3: Kehua Data - Kehua Data's revenue for 2024 is expected to be 7.757 billion yuan, a decrease of 4.71% year-on-year, with a net profit of 315 million yuan [3] - The intelligent computing center business has seen a revenue increase of 14.07%, while the new energy business revenue has decreased by 15.98% [3] - The company plans to enhance its intelligent computing center business and has completed a convertible bond project for future funding [3] Group 4: Tongyu Communication - Tongyu Communication's growth in the first quarter is attributed to increased overseas revenue and contributions from satellite communication [4] - The company is focusing on R&D in satellite communication and 5G integrated antennas, achieving significant results [4] - Future plans include targeting high-end markets and leveraging overseas advantages to assist domestic satellite manufacturers [4]

Group 1: Company Performance and Orders - In 2024, the company expects to achieve approximately 1.515 billion CNY in new orders, representing a year-on-year growth of about 30.07% [2] - The company anticipates that the growth rate for new orders in the traditional Chinese medicine CRO sector will be around 20%, accounting for approximately 30% of total new orders in 2024 [3] - As of the end of 2024, the company has unrecognized revenue from contracts amounting to approximately 2.759 billion CNY, with an expected 682 million CNY to be recognized as revenue in 2025 [4] Group 2: Market Conditions and Competition - The CRO market remains highly competitive, with some smaller CRO companies facing operational difficulties, layoffs, or even liquidation, leading to an expected increase in industry concentration [3] - The company maintains a strong competitive advantage due to its established presence and resources in the CRO market [3] - The nuclear medicine CRO market is emerging, with few companies having relevant project experience, which positions the company favorably for future projects [8] Group 3: Profitability and Margins - The company expects the gross margin for clinical business to slightly decline due to ongoing market competition, while the gross margin for preclinical business remains stable [4] - Despite the anticipated decline in gross margin, the company is focused on reducing costs and believes that net profit margins will not decrease [4] Group 4: Future Plans and Innovations - The company plans to continue focusing on clinical services while also developing preclinical research and drug evaluation services, as well as contract development and manufacturing organization (CDMO) services [6] - There are ongoing discussions for the transfer of self-developed projects, with expectations to achieve significant milestones in 2025 [5] - The company is actively exploring AI applications in clinical trial design and data analysis, with plans to expand its use in clinical monitoring and preclinical compound screening [9]

Core Viewpoint - 博济医药's 2024 annual report indicates significant revenue growth, but also highlights notable quarterly fluctuations in performance metrics [1] Financial Performance - The company achieved total revenue of 742 million yuan, representing a year-on-year increase of 33.50% [1] - Net profit attributable to shareholders was 28.78 million yuan, up 18.23% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 19.30 million yuan, showing a substantial increase of 92.71% year-on-year [1] - However, there were quarterly declines, with total revenue rolling quarter-on-quarter down by 1.48%, net profit down by 35.47%, and net profit excluding non-recurring items down by 38.24% [1] Revenue Breakdown - Clinical research services revenue reached 597 million yuan, a significant increase of 44.12% year-on-year, with new contract value growing by 38.56% to 1.305 billion yuan [5] - Preclinical research services revenue was 84.32 million yuan, reflecting a growth of 7.70% year-on-year, with new contract value around 158 million yuan [6] - Other consulting services revenue decreased by 13.02% year-on-year to 42.22 million yuan, with new contract value approximately 5.2 million yuan [7] Business Segments - The company continues to lead in traditional areas such as liver disease, oncology, and endocrinology while making breakthroughs in emerging fields like immunology and gene therapy [5] - In the medical device sector, the company conducted nearly 80 clinical research services and 40 registration services, securing 13 Class III medical device registrations [5] - The company has established partnerships with over 900 clinical trial service organizations and signed strategic cooperation agreements with more than 40 institutions [5] R&D and Innovation - The company has received over 10 invention patents and is progressing well with multiple self-research projects [8] - The drug evaluation center successfully passed the GLP qualification re-examination and received the GLP certification [6] - AI technology is being utilized in the design of new target compounds to enhance research efficiency and accuracy [6]